01093 CSPC PHARMA
- 6.620
- +0.020+0.30%
CSPC PHARMA News
CSPC Group (01093.HK): The trustee purchased 4.79 million shares under the share incentive plan
Gelonghui, April 26, 丨 Shiyao Group (01093.HK) announced that on April 26, 2024, the plan trustee (“trustee”) purchased a total of 4.79 million shares of the company on the market in accordance with the terms and conditions of the plan and held such shares in trust for the benefit of the selected participants.
CSPC Group (01093.HK): Highly selective MAT2A inhibitor (SYH2039) approved for clinical trials in the US
Gelonghui, April 26, 丨 Shiyao Group (01093.HK) announced that the Class 1 new chemical highly selective MAT2A inhibitor (SYH2039) developed by the Group has been approved by the US Food and Drug Administration (FDA) and can conduct clinical trials in the US. Previously, the product was approved by China's National Drug Administration in March 2024, and clinical trials can be carried out in China. SYH2039 is a highly active methionine adenoganase 2A (MAT2A) inhibitor that selectively kills MTAP-deficient tumor cells and has little effect on normal cells
石藥集團：2023年度報告
CSPC Pharmaceutical's EBT Buys 8.5 Million Shares
CSPC Pharmaceutical Group's (HKG:1093) employee benefit trust (EBT) purchased close to 8.5 million CSPC shares via two transactions on the secondary market this week, according to separate filings wit
CSPC Group (01093.HK): The trustee purchased 5.54 million shares under the share incentive plan
Gelonghui, April 24, 丨 Shiyao Group (01093.HK) announced that on April 24, 2024, the plan trustee (“trustee”) purchased a total of 5.54 million shares of the company on the market in accordance with the terms and conditions of the plan and held such shares in trust for the benefit of the selected participants.
Shiyao Group (01093): The trustee purchased a total of 2,934 million shares under the share award scheme
Shiyao Group (01093) issued an announcement. On April 23, 2024, the plan trustee, in accordance with the terms of the plan and...
Shiyao Group: The net profit of CSPC Innovation in the first quarter was about 79.0613 million yuan, a year-on-year decrease of 38.86%
Shiyao Group (01093) announced the results of Shiyao Innovation (300765.SZ) for the first quarter of 2024, with operating income of about 524 million yuan, a year-on-year decrease of 27.08%; net profit attributable to shareholders of listed companies was about 79.0613 million yuan, a year-on-year decrease of 38.86%; and basic earnings per share were 0.0676 yuan.
Shiyao Group (01093): The net profit of Shiyao Innovation (300765.SZ) in the first quarter was about 79.0613 million yuan, a year-on-year decrease of 38.86%
According to Zhitong Finance App News, Shiyao Group (01093) announced the results of Shiyao Innovation (300765.SZ) for the first quarter of 2024, with operating revenue of about 524 million yuan, a year-on-year decrease of 27.08%; net profit attributable to shareholders of listed companies was about 79.0613 million yuan, a year-on-year decrease of 38.86%; and basic earnings per share were 0.0676 yuan. According to the announcement, the main reason for the decline in revenue was the decline in main business revenue during the reporting period due to a decrease in the price of caffeine products compared to the same period last year. At the same time, Jushi Biotech authorized the overseas development and commercialization of Nectin4 ADC products during the same period last year
石藥集團：內幕消息 - 石藥創新製藥股份有限公司截至2024年3月31日止3個月之主要財務資料
CSPC Group (01093.HK) spent HK$27.5927 million to buy back 4.628 million shares on April 22
Gelonghui, April 22丨Shiyao Group (01093.HK) announced that it spent HK$27.5927 million to buy back 4.628 million shares on April 22.
CSPC Group (01093.HK) awards 300,000 restricted shares
Gelonghui, April 22丨Shiyao Group (01093.HK) issued an announcement. On April 22, 2024, according to the restricted share award scheme adopted on August 20, 2018, a group employee (who is not a director, CEO or major shareholder or contact person of any of them) will be awarded 300,000 restricted shares, subject to acceptance by the grantor.
CSPC Group (01093.HK) spent HK$34.5693 million to buy back 6 million shares on April 19
Gelonghui, April 19 | Shiyao Group (01093.HK) announced that on April 19, it spent HK$34.5693 million to repurchase 6 million shares, with a repurchase price of HK$5.66-5.82 per share.
Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
It's not a stretch to say that CSPC Pharmaceutical Group Limited's (HKG:1093) price-to-earnings (or "P/E") ratio of 10.9x right now seems quite "middle-of-the-road" compared to the market in Hong Kon
CSPC Group (01093) spent about HK$294.427 million to buy back 5 million shares on April 18
CSPC Group (01093) announced that the company spent approximately 294.427 million on April 18, 2024...
CSPC Group (01093) spent HK$349.292 million to buy back 6 million shares on April 17
Shiyao Group (01093) announced that on April 17, 2024, the company spent 349.292 million...
CSPC Group (01093.HK) spent HK$29.082 million to buy back 5 million shares on April 16
Gelonghui, April 16, 丨 Shiyao Group (01093.HK) announced that it spent HK$29.082 million to buy back 5 million shares on April 16.
CSPC Group (01093): A total of 19.5 million new shares were allotted to management grantees on April 15
Shiyao Group (01093) issued an announcement. On the date of this announcement, the conditions for the ownership of the first batch of share purchase rights have been fulfilled. At 2...
CSPC Group (01093.HK): Exercise of share options under the share option scheme
Gelonghui April 15 丨 Shiyao Group (01093.HK) issued an announcement. On the date of this announcement, the conditions for the ownership of the first batch of share options have been fulfilled. On April 11, 2024, a total of 19.5 million share options (as part of the first batch of share options) were exercised by several management grantees at an exercise price of HK$5.98 per share (“exercise of the first batch of share options”).
Shanghai Securities: A new mechanism for oral antihypertensive drugs has been approved by the FDA for marketing, and attention is being paid to the cardiovascular drug circuit
The Zhitong Finance App learned that Shanghai Securities released a research report saying that on March 19, the US FDA announced approval for the launch of Tryvio, a new molecular physical drug developed by Idorsia. Tryvio is an endothelin receptor antagonist used to treat high blood pressure that is still insufficiently controlled when combined with other antihypertensive drugs. Notably, Tryvio is the first oral antihypertensive therapy approved to work through a new treatment route in nearly 30 years. According to the “China Cardiovascular Health and Disease Report 2022”, the prevalence of cardiovascular disease in China continues to rise. The current number of patients is estimated to be 330 million.
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights CSPC Pharmaceutical Group's estimated fair value is HK$9.57 based on 2 Stage Free Cash Flow to Equity CSPC Pharmaceutical Group's HK$6.15 share price signals that it might be 36% underv
Analysis
Price Target
No Data
